Pictet Biotech Inclusive - Class P - Income (GBP)
Charges and Savings
Initial charges | |
---|---|
Initial charge: | 0.00% |
Initial saving from HL: | 0.00% |
Net initial charge: | 0.00% |
HL dealing charge: | Free |
Annual charges | |||
---|---|---|---|
Performance fee: | No | ||
Ongoing charge (OCF/TER): | 2.00% | ||
Ongoing saving from HL: | 0.80% i | ||
Net ongoing charge: | 1.20% | ||
There are other unit types of this fund available: | |||
|
In some cases the ongoing savings are provided by our loyalty bonus. Loyalty bonuses are tax-free in an ISA or SIPP. However, they may be subject to tax in a Fund & Share Account which would, in effect, reduce their value and increase the net ongoing charge.
Other Information
Ready to invest?
To invest in , you'll need to have an account. Try our handy filter to explore the different options.
Ready to take your first step?
To invest in , you'll need to open an account. Try our handy filter and find out which suits you best.
Performance
07/11/19 to 07/11/20 | 07/11/20 to 07/11/21 | 07/11/21 to 07/11/22 | 07/11/22 to 07/11/23 | 07/11/23 to 07/11/24 | |
---|---|---|---|---|---|
Annual return | 33.84% | -0.13% | -7.88% | -14.70% | 33.10% |
Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.
View fund chartOur view on this fund
The Wealth Shortlist features funds our analysts believe have the potential to outperform their peers over the long term. If a fund is not on the Shortlist, this is not a recommendation to sell; however, if you are thinking of adding to your investments, we believe the Wealth Shortlist is a good place to start. View funds on the Wealth Shortlist »
Fund Objective
The sub-fund seeks capital growth by investing at least two-thirds of its total assets in the shares of particularly innovative companies operating in medical biotechnology. The investment universe is not restricted to a specific geographical zone. However, given the particularly innovative nature of the pharmaceutical industry in North America and Europe, the vast majority of investments will be made in this zone.
Income Details
Security | Weight |
---|---|
GILEAD SCIENCES INC | 5.98% |
ARGENX SE | 5.80% |
REGENERON PHARMACEUTICALS INC | 4.95% |
ALNYLAM PHARMACEUTICALS | 4.28% |
INSMED INC | 3.99% |
SAREPTA THERAPEUTICS | 3.57% |
INTRA-CELLULAR THERAPIES | 3.39% |
ZEALAND PHARMA A/S | 3.05% |
VAXCYTE INC | 3.05% |
AMGEN | 2.89% |
Sector | Weight |
---|---|
Pharmaceuticals & Biotechnology | 96.84% |
Medical Equipment & Services | 1.47% |
Managed Funds | 1.41% |
Cash and Equiv. | 0.28% |
Non-Classified | 0.00% |
Country | Weight |
---|---|
United States | 82.71% |
Netherlands | 8.46% |
Denmark | 3.55% |
Canada | 1.60% |
Managed Funds | 1.41% |
United Kingdom | 1.06% |
Mexico | 0.55% |
France | 0.38% |
Cash and Equiv. | 0.28% |
Non-Classified | 0.00% |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by Morningstar, correct as at 7 November 2024. Data provided by Broadridge, correct as at 30 September 2024.
4 If you elect to receive the income from an ISA or a Fund & Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.